Five Questions with Dr. Joanne Santomauro

April 28, 2021
In “Five Questions,” we speak with Dr. Joanne Santomauro, founder and CEO of Ancillare, about the work her company has been doing throughout the COVID-19 pandemic, leadership during crisis and what the business is doing to support advancements in women’s healthcare and pharmaceuticals.

1.  Tell us about Ancillare. Why did you found the business?

It is a long story that I’ll shorten: One of our sponsors asked us to assist them with issues they were having with ancillary supplies for their clinical trials. These issues involved numerous areas because of increased global regulatory oversight, including approved product selection, maintaining current calibrations of equipment, standardization of supplies utilized, and so forth.

We began working with this sponsor and soon realized this was a pain point that most pharmaceutical, contract research and biotechnology organizations were experiencing. They had little transparency to the overall supply chain and a limited grasp of the associated costs, processes and regulatory and compliance requirements of this diverse global supply chain.

My team began conducting extensive field research. My son, an MBA student at Cornell University at the time, also utilized university experts and research centers to assist with this project. Our research confirmed my hypothesis – this was indeed a universal problem that needed a solution. In 2006, I took my more than 35 years of supply chain experience and launched the market-leading model Clinical Trial Ancillary Supply Chain (CTASCTM) management.

2.  Like many businesses, Ancillare was greatly impacted by the events of 2020. What role has the business played throughout the COVID-19 pandemic?

COVID-19 posed numerous supply chain challenges never experienced in any of our lifetimes. Borders and countries were shut down, commerce was all but halted, patients feared venturing outside of their homes and trials were paused. Critical clinical trial supplies required to conduct COVID-19 trials, such as needles, syringes, caps, IV lines, thermometers, etc. – all of which were readily available prior to the pandemic – were in extreme short demand. Plus, the U.S. government and hospitals were first in the factories’ lines of production to receive shipments. Furthermore, requests for medical devices and equipment surged, and Ancillare, as the preferred supplier for our sponsors for numerous COVID-19 trials, needed to formulate our response to achieve success. Again, it is a long, arduous story: Ancillare identified and qualified factories ready to accept our large quantity of more than 1 million purchase order requests for various supplies. Factory orders were placed, and shelves were stocked – all in advance of Ancillare’s receipt of sponsors’ purchase orders. The result was that 100% of all sponsor requests for shipments were released prior to first patient first visit at global clinical sites.

Trumping these supply chain challenges was the need to maintain the physical and mental health of our essential workers and our work-at-home teams. Managing clinical trials, and especially COVID-19 trials, involves demanding, difficult work. Ancillare team members embrace our mission that our shipments touch the most critically ill patients looking for cures to what ails them; thus, the need for perfection is necessary in our areas of performance. This is a very heavy burden, and I personally am very sensitive to the needs of our people.

3.  What lessons have you learned about leadership through crisis?

The biggest lesson that Ancillare has learned during these very unfortunate times is that proactivity and teamwork are essential to deliver success. Ancillare teams worked 24/7 during the course of the pandemic. Essential elements of focus were engaging factories and funding the pipeline to initiate prepayments, so that all Ancillare purchase order requests were pushed to the front of the factory production lines. Even though the pandemic is subsiding, the supply chain issues, recalls and shortages will continue for the next few years, and Ancillare’s approach to CTASCTM management remains as diligent as in the first months of the pandemic.

4.  What role is the business playing to support advancements in women’s healthcare and pharmaceuticals?

Ancillare assists sponsors worldwide to manage their women’s health clinical trials and deliver patient-centric CTASCTM management. In addition, we have a medical director on staff whose expertise is in women’s health, and this professional advises our sponsors specifically in this therapeutic area. Over the past five years, we have seen our clients focus more on women’s health clinical trials, and we are confident that Ancillare’s expertise will enable us to not only educate but also help to bring novel therapies to market.

5.  What advice would you give your younger self?

I am a perfectionist and want every aspect of our work to be perfect in all deliverables. CTASCTM management is difficult. Many areas are totally outside of our control, such as changes in the clinical trial protocol, border strikes, availability of supplies in the marketplace – all this and more can impact our success. I would tell my younger self to breathe, be calm and think through the solution. These suggestions would have served me and my teams well over the course of my career.

Up Next
Up Next

Women & Wealth Magazine Winter Issue 2021

In this issue of Women & Wealth Magazine, we kick off the new year with a focus on wellness, which is particularly important in the time of COVID-19 and all of its many implications for our daily lives.

Brown Brothers Harriman & Co. (“BBH”) may be used as a generic term to reference the company as a whole and/or its various subsidiaries generally. This material and any products or services may be issued or provided in multiple jurisdictions by duly authorized and regulated subsidiaries.This material is for general information and reference purposes only and does not constitute legal, tax or investment advice and is not intended as an offer to sell, or a solicitation to buy securities, services or investment products. Any reference to tax matters is not intended to be used, and may not be used, for purposes of avoiding penalties under the U.S. Internal Revenue Code, or other applicable tax regimes, or for promotion, marketing or recommendation to third parties. All information has been obtained from sources believed to be reliable, but accuracy is not guaranteed, and reliance should not be placed on the information presented. This material may not be reproduced, copied or transmitted, or any of the content disclosed to third parties, without the permission of BBH. All trademarks and service marks included are the property of BBH or their respective owners.© Brown Brothers Harriman & Co. 2021. All rights reserved. PB-04479-2021-04-16

This browser is not fully supported by our public website and may not display or function as expected for this reason. Please note, the Infuse Portal and BBH client applications fully support the IE 11 browser.

Important Information for Non-U.S. Residents

You are required to read the following important information, which, in conjunction with the Terms and Conditions, governs your use of this website. Your use of this website and its contents constitute your acceptance of this information and those Terms and Conditions. If you do not agree with this information and the Terms and Conditions, you should immediately cease use of this website. The contents of this website have not been prepared for the benefit of investors outside of the United States. This website is not intended as a solicitation of the purchase or sale of any security or other financial instrument or any investment management services for any investor who resides in a jurisdiction other than the United States1. As a general matter, Brown Brothers Harriman & Co. and its subsidiaries (“BBH”) is not licensed or registered to solicit prospective investors and offer investment advisory services in jurisdictions outside of the United States. The information on this website is not intended to be distributed to, directed at or used by any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation. Persons in respect of whom such prohibitions apply must not access the website.  Under certain circumstances, BBH may provide services to investors located outside of the United States in accordance with applicable law. The conditions under which such services may be provided will be analyzed on a case-by-case basis by BBH. BBH will only accept investors from such jurisdictions or countries where it has made a determination that such an arrangement or relationship is permissible under the laws of that jurisdiction or country. The existence of this website is not intended to be a substitute for the type of analysis described above and is not intended as a solicitation of or recommendation to any prospective investor, including those located outside of the United States. Certain BBH products or services may not be available in certain jurisdictions. By choosing to access this website from any location other than the United States, you accept full responsibility for compliance with all local laws. The website contains content that has been obtained from sources that BBH believes to be reliable as of the date presented; however, BBH cannot guarantee the accuracy of such content, assure its completeness, or warrant that such information will not be changed. The content contained herein is current as of the date of issuance and is subject to change without notice. The website’s content does not constitute investment advice and should not be used as the basis for any investment decision. There is no guarantee that any investment objectives, expectations, targets described in this website or the  performance or profitability of any investment will be achieved. You understand that investing in securities and other financial instruments involves risks that may affect the value of the securities and may result in losses, including the potential loss of the principal invested, and you assume and are able to bear all such risks.  In no event shall BBH or any other affiliated party be liable for any direct, incidental, special, consequential, indirect, lost profits, loss of business or data, or punitive damages arising out of your use of this website. By clicking accept, you confirm that you accept  to the above Important Information along with Terms and Conditions.

 
1BBH sponsors UCITS Funds registered in Luxembourg, in certain jurisdictions. For information on those funds, please see bbhluxembourgfunds.com


captcha image

Type in the word seen on the picture

I am a current investor in another jurisdiction